Clinical Trial Update: A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety and efficacy trial of Eplontersen for hereditary transthyretin-mediated amyloid polyneuropathy is ongoing and currently not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Transthyretin-mediated Amyloid Polyneuropathy

Drugs mentioned

• Eplontersen (eplontersen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Phase 3 | Status: ACTIVE_NOT_RECRUITING